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Monogenic primary hypercholesterolaemia in
South Africa
D. C. RUBINSZTEIN, D. R. VAN DER WESTHUYZEN, G. A. COETZEE
Abstract Familial hypercholesterolaemia (FH) and familial
defective apolipoprotein B-IOO (FDB) are the
two major causes of monogenic primary hyper-
cholesterolaemia. In this review, FH and FDB
are defined in relation to normal lipoprotein
metabolism. In South Africa FH affects about 1%
of Afrikaners,jews and Indians, while FDB is
probably a much rarer disorder. In Afrikaners,
three 'founder' mutations are responsible for
more than 80% of FH. The population genetics
that created the exceptionally high frequency of
FH and comparatively low frequency of FDB in
various South African populations are described.
The genetic organisation and itinerary of the nor-
mal low-density lipoprotein (LDL) receptor are
reviewed, with particular emphasis on the struc-
ture-function relationships in the LDL receptor
that have been clarified by the mutations found in
South Africa. Finally, the clinical relevance of
research into FH in South Africa is discussed.
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sity lipoprotein (LDL) receptor since chylomicron rem-
nant clearance is unimpaired in FH homozygotes with
severe LDL-receptor deficiency.· The lY2 macroglobulin
receptor, also known as the LDL receptor-related protein
(LRP), might be the chylomicron remnant receptor.7
FIG. 1.
Schematic diagram of the exogenous lipoprotein path-
way.
FIG. 2.
Schematic diagram of the endogenous lipoprotein path-
way (VLDL =very-Iow-density lipoprotein; IDL =inter-
mediate-density lipoprotein; LDL = low-density lipopro-
tein).
The 'endogenous' lipoprotein pathway involves the
metabolism of lipoproteins secreted by the liver (Fig. 2).
These triglyceride-rich particles are known as very-low-
density lipoproteins (VLDL). The triglycerides of
VLDL are lipolysed by lipoprotein lipase to yield smaller
particles called intermediate-density lipoproteins (IDL).
These IDL are either lipolysed funher by lipoprotein
lipase or hepatic lipase to form LDL or removed directly
from the circulation by LDL receptors. LDL panicles,
which carry most of the plasma cholesterol, are removed
from the circulation mainly by hepatic LDL receptors.
Although approximately 70% of LDL catabolism is via
the liver, which is the major exit route of cholesterol
from the body, significant LDL clearance from the
blood is mediated by the small intestine, skeletal muscle,
kidney and spleen.
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F amilial hypercholesterolaemia (FH) and familialdefective apolipoprotein B-lOO (FDB) are the twomajor causes of monogenic primary hyperchole-
sterolaemia. Both of these autosomal dominant disor-
ders have a prevalence of 1/500 in American and
European populations and are among the commonest
known Mendelian diseases. l ,1 Since FH is particularly
common (> 1/100) in the Afrikaner,' Jewish· and Indian
populations of South· Africa (personal communication
- H. C. Seftel, M. S. Asvat), an awareness of this
disease on the part of medical practitioners is desirable.
The physiological consequences of these monogenic
disorders are best appreciated in the context of normal
lipoprotein metabolism. Intravascular lipoprotein meta-
bolism involves interconversions between lipoprotein
types, exchange of lipoprotein components and final cel-
lular clearance. Two different pathways ensure lipopro-
tein metabolism in the blood. I.; The 'exogenous' pathway
entails the transpon of dietary lipid from the intestine to
the rest of the body, while the 'endogenous' pathway is
responsible for the transpon of dietary and newly synthe-
sised lipid from the liver to extrahepatic cells.
In the 'exogenous' pathway (Fig. 1), triglycerides and
cholesterol are absorbed by the intestine where they are
subsequently packaged into chylomicron panicles which
are secreted into the lymphatic system to enter the circu-
lation via the thoracic duct. The triglycerides in these
large lipoproteins are hydrolysed by lipoprotein lipase on
the surface of the vascular endothelium. The resultant
smaller chylomicron remnants are removed from the
blood mainly by receptors on parenchymal liver cells.
These receptors are probably distinct from the low-den-
~'-----------~----...
Monogenic disorders that result in
impaired LDL metabolism
Impaired removal of LDL is the primary defect in the
two related syndromes, FH and FDB.
FH is an autosomal dominant disorder that results
from mutations at the LDL-receptor gene locus that
affect either the number and/or function of the LDL-
receptor protein.S This has nvo different effects on the
endogenous lipoprotein pathway that cause hyper-
cholesterolaemia. First, the rate of LDL removal is
decreased and second, the production of LDL from
IDL is increased as a result of impaired IDL clearance
from the circulation. More than 50 different mutations
that affect one or more vital facets of LDL-receptor
function have been described.s The clinical severity of
this disease is milder in patients with one mutant gene
(heterozygotes) than in those with two (homozygotes).
Heterozygotes express approximately 50% of the normal
number of functional LDL receptors on their cells.
Their plasma cholesterol levels are consequently about
nvice as high as normal and coronary heart disease
is 25 times more common in heterozygotes than in
unaffected persons. The situation in homozygotes who
have two mutant alleles is even more severe: plasma
cholesterol concentrations are raised up to five times
the normal concentrations and coronary artery disease
often manifests in childhood and frequently leads to
death from a heart anack before the age of 25 years. I,'
Xanthomata, xanthelasmata and corneal arci are visible
manifestations of cholesterol deposition that are in-
variant in FH homozygotes and variable in FH hetero-
zygotes. I,'
An alternative genetic disorder, described more
recently, that causes pathologically decreased LDL
clearance is FDB.2 This disorder is caused by a glu-
tamine for arginine substitution at codon 3500 of apo B.
Apo B-I00 is the sole apoprotein on LDL and is the lig-
and on the particle that is bound by the LDL receptor.
The LDLs that carry the mutant apo B bind very poorly
to LDL receptors and are cleared abnormally slowly
from the circulation. FDB in its heterozygous state is
clinically very similar to heterozygous FH! In contrast
to FH, FDB is caused by one mutation that probably
occurred only once on an ancestral Caucasian chromo-
some. 2 Although the frequency of FDB in North
American and European populations is approximately
11500/ this mutation has not been detected in FinnslO or
in Japanese.1l
FH in South Africa
FH has been a' focus of research in South Africa ever
since Seftel et al. 3 recognised it as a common disease
among Afrikaners. The same researchers recognised
later that FH was also prevalent among Indians and
Jews in South Africa! The frequency of FH in these
populations is among the highest in the world. In
Afrikaners and South African Jews, the high frequency is
probably due to a 'founder effect'. 3,'
The history of the settlement of the Afrikaners in
South Africa serves as a classic example of the factors
contributing to the so-called 'founder effect'. The
majority of South Africa's present-day 2 million
Afrikaners are descended from about 2 000 senlers of
Dutch, German and French origin who arrived in South
Africa in the late 17th and early 18th centuries. Given
their small numbers and statistical chance, these senlers
as a group had higher (or lower) frequencies of cenain
disease alleles than their original parent European popu-
lations. This was the result of chance over- or under-
sampling of rare alleles. The odds of such occurrences
are inversely proportional to the size of the senler popu-
lation. This population maintained its particular genetic
constitution as it expanded since, until recently,
Afrikaners generally only married Afrikaners. These
altered allelic frequencies were prone to further amplifi-
cation or reduction by the random genetic drift to which
small populations are prone. The Afrikaner population
expanded far faster than its European counterparts by
growing about 1 ODD-fold in 300 years. 3,S,12
Three founder type mutations, FH Afrikaner-l, FH
Afrikaner-2 and FH Afrikaner-3, have now been identi-
fied l3,14 and account for approximately 90% of the
monogenic hypercholesterolaemia in this population. 12,15
All three of these mutations have been detected in the
Netherlands. 16
South African Jews of Eastern European (Ashken;:m)
descent also have a particularly high incidence ot FH
(> 1/100)! The predominant mutation in this popula-
tion is FH Piscataway." The majority of this population
are descendants of 40 000 Lithuanian immigrants who
senled in South Africa between 1889 and 1910. In this
case it is unlikely that a founder effect could have mani-
fested in three or four generations from a relatively large
starting population. Since this mutation also accounts
for 35% of FH in Ashkenazi Israelis, it is more likely
that a founder effect occurred in Lithuania. This muta-
tion is particularly interesting since evidence of its
founder origin is visible in many Ashkenazi Jewish fami-
lies throughout the world. 11
Another South African group that seems to have a
particularly high incidence of FH (> 1/100) is the
Indian population (personal communication - H.
Seftel, M. Asvat). South African Indians are almost
entirely descended from 150 000 immigrants who set-
tled in South Africa between 1860 and 1911. The
majority of these people were indentured labourers who
originated in many different regions on the south and
east coasts of India. A minority Oess than 30 000) were
traders and artisans who paid their own passage to
South Africa. This group, known as the 'passenger
Indians', came from areas in the Gujerat province on
the west coast of the subcontinent. About 50% of these
people came from the Surat and Valsad districts. The
other major source of passenger Indians was Kathiowar
on the Arabian Sea. IS The Indian population of South
Africa is of diverse cultural apd religious origin; the
majority (65%) of the population are Hindus (many of
the castes are represented) and there are a significant
number of Muslims (21 %) and Christians (7,5%).
At least four different mutations cause FH in this
population (unpublished results - D. C. Rubinsztein,
G. A. Coetzee, D. R. van der Westhuyzen). One of
these mutations, FH Zambia, was originally described
in a Muslim Zambian of Gujerati origin.19 This muta-
tion has been identified in four unrelated families in
South Africa20 and in' another Indian patient in the
UK. 2 1 All of these people were Muslims of Gujerati
descent. This suggests that this mutation might be very
common in Gujerat, possibly as a result of a founder
effect in that region of India. This mutation possibly
spread all over the world wherever Muslim Gujeratis
settled, in a manner analogous to the FH Piscataway
mutation in Lithuanian Jews.
FH seems to be relatively rare in black South
Africans.22 This might be due to a decreased frequency
of mutant genes in this population. Alternatively,
because most rural blacks eat low fat diets and have
relatively low cholesterol levels, FH might not be recog-
nised readily. The hypothesised genetic protection
against hypercholesterolaemia found in blacks23 might
also mask FH. However, two different black FH
homozygotes have been identified; a Xhosa homo-
allelic homozygote, i.e. he inherited twO identical




Slow processing; 2 populations of
receptors, one with defective binding
Slow processing; rapid degradation
Slow processing; decreased affinity
for LDL at 37°C; increased precursor
degradation
Does not recognise LDL; rapid
degradation in absence of f3-VLDL is
enhanced in the presence of f3-VLDL
Slow processing
Slow processing; rapidly degraded
Molecular biology of the South African
LDL-receptor mutations
The genetic organisation and itinerary of
the LDL receptor
The LDL-receptor gene is a highly mutagenic locus
responsible for sUStaining the high frequency of FH. It
has twice as many 'Alu' repeats as the average human
gene.· These Alu repeats, which are the commonest
'middle repetitive' DNA sequences in humans, are hot-
spots for recombination events. Seven of the eight large
deletions in the illL receptor that have been sequenced
involve Alu repeats. The other mutagenic mechanism
that seems to operate at this locus is the transition of
cytosine to thymine at CpG dinucleotides containing
methylated cytosines.· More than 44% ofillL-receptor
point mutations can be accounted for by this process.
The FH Afrikaner-2,13.14 FH Zambia" and FH Durban-
228 mutations are such cytosine-to-thymine transitions.
The 860 amino acid LDL receptor is a multi-domain
protein with components of diverse evolutionary origin.s
Its gene of 45 kB is found on the short arm of chromo-
some 19 and is transcribed into a 5,3 kB mRNA. The
exons are arranged in modules where each exon or
group of exons defines a distinct domain of the receptor
(Fig. 3). Exon 1 codes for a short 5' untranslated region
and a 21-amino acid signal sequence that aids in the co-
translational translocation of the protein into the endo-
plasmic reticulum (ER). This region is cleaved off dur-
ing the translocation process to yield a mature protein of
839-amino acid. Exons 2-6 code for the receptor's
ligand-binding domain that consists of seven cysteine-
rich 40-amino acid repeats homologous to the comple-
ment factor 9. Exons 7-14 code for a domain homolo-
gous to a region of the EGF-precursor molecule and
exon 15 codes for 58-amino acids that are rich in anach-
ment sites for O-linked sugars. Exon 16 and part of
exon 17 code for the membrane-spanning domain and
the rest of exon 17 and part of exon 18 code for the
cytoplasmic tail of the receptor.
illL-receptor proteins are synthesised on polyribo-
somes and are co-translationally inserted into the ER,
where glycosylation starts to occur (Fig. 4). At this point
the precursor receptor has an apparent MW of 120 kDa.
After transport to the Golgi where the sugars are modi-
Deletion exon 7 and 8
3 b.p. deletion of gly 197 exon 4
Codon 664 pro to leu exon 14
Codon 69 asp to tyr exon S
Codon 119 glu to Iys exon 4
Null mutation, site unknown
6 b.p. deletion asp-26 gly-27 exon 2
3 b.p. deletion in repeat 1 of
promoter
Codon 206 asp to glu exon 4
Gene defect
Codon 408 val to meth exon 9

























FH Afrikaner-1 13•3 '
FDB does not seem to be as frequent a cause of mono-
genic hypercholesterolaemia among South African
Afrikaners, coloureds, Indians and blacks as it is in
American and European populations (unpublished
results - D. C. Rubinsztein, M. Kotze, G. A. Coetzee
and D. R van der Westhuyzen). A possible reason for
tbe rarity of this disorder in Indians and blacks is that
the gene is of Caucasian founder origin. Any FDB that
arrived in the coloured gene pool from their European
ancestors would have been diluted. Although FDB
seems to be quite common in the Netherlands," it is
comparatively rare among Afrikaners. Perhaps this
represents a negative founder effect where by chance
FDB was underrepresemed in South African settler
populations.
The susceptibility of the LDL-receptor and apolipo-
protein B genes to mutations is probably similar in all
populations and neither FDB nor FH seems to confer
obvious heterozygote disadvantages in affected individu-
als. Therefore, it is likely that random genetic drift and
founder effects are major determinants of the frequency
of primary monogenic hypercholesterolaemia in differ-
ent populations. This is exemplified in South Africa, a
country with many different recent founder populations,
where FH in Afrikaners, Jews and Indians is five times
more frequent than in most other populations and
where FDB is comparatively rare.
TABLE!.
LDL-receptor mutations in South Africa
mutam genes called FH Cape Town-l/" and a Pedi
hetero-allelic homozygote who had two different muta-
tions (both distinct from FH Cape Town-P). Both
patients died of complications of coronary heart disease.
The so-called coloured population of South Africa
have all three of the Afrikaner founder mutations'
(unpublished results - F. Graadt van Roggen, M.
Kotze). In addition, they also have the FH Cape Town-
2 mutation/· now known to be one of the most com-
mon mutations found in the Netherlands.'· The illL-
receptor mutations that have been identified to date in
the various populations in South Africa are listed in
Table 1. The abnormalities in LDL-receptor exPression
that result from these mutations are also summarised
and will be discussed below.













cholesterol is transported out of the lysosome. It has
many regulatory consequences, including the stimula-
tion of intracellular cholesterol esterification and the
down-regulation of LDL receptor and de novo choles-
terol synthesis.'>'
The unoccupied receptors return from the CURL to
the cell surface where they can undergo many further
rounds of endocytosis. Each round trip takes about 12
minutes.' The receptors are degraded with a half-life of
10 - 12 hours, probably in a non-lysosomal compart-
ment."
The diverse mutations in the LDL-receptor have
been grouped into 5 classes depending on the resulting
disturbance in function.' Manv mutations result in dis-
turbances of more than one fa~et of normal LDL recep-





Structure-function relationships in the
LDL receptor that have been clarified by
the South African Inutations
Class 1 mutations produce no detectable receptors.
These mutations often result from large deletion,s of the
gene's promoter that produce no detectable mRNA, e.g.
the most common of the French-Canadian founder
mutations.' Most of the control of LDL-receptor
expression is thought to be at the transcriptional level.'
One of the mutations in the South African Pedi is possi-
bly an interesting case of a class 1 mutation in that 3
b.p. are deleted from the promoter in a region where the
positive transcription factor, SpI", is thought to bind."
Studies are under way to establish the consequences of
this mutation on transcription. Class 1 mutations can
also be caused by nonsense mutations or deletions that
create premature stop codons.
Class 2 mutations result in receptors that are either
. slowly transported from the ER to the Golgi or retained
in the ER This manifests in a delay in conversion of the
precursor receptor (120 kDa) to its mature form (160
kDa).' This phenomenon is probably due to the inter-
action of the mutant proteins with 'gate-keeper' proteins
that prevent transport of malfolded proteins out of the
ER The FH Cape Town-I" mutant receptor that has a
deletion of 2 amino acids in the first ligand-binding
domain repeat is a classic example of such a mutation.
Since the deletion of the entire first repeat had no effect
on protein transport,'O it seems that each ligand-binding
repeat functions as a semi-independent module. The
small deletion in FH Cape Town-I probably disrupts
the protein folding within the first repeat to cause a class
2 mutation. A similar phenomenon is found in FH
Piscataway,' a deletion of 1 amino acid in the 4th
ligand-binding domain repeat. This phenomenon is also
found in many of the South African mutations, includ-
ing the 3 Afrikaner·founder mutations 13>3l and FH
Zambia. '.>'0 A delay in receptor transport alone, as
opposed to a complete block, is not sufficient to cause a
decreased pool of cell surface receptors. A decreased
surface receptor number will only occur if there is
impaired synthesis or increased degradation of precursor
or mature receptors. Normally, no precursor degrada-
tion occurs and there is complete conversion of all the
precursors to the mature forms! The FH Afrikaner-3
receptor is an example of a mutation that results in
slowed transport and degradation of precursors (the
mature receptor has normal stability) (unpublished
results - F. Graadt van Roggen, G. A. Coetzee, D. R
van der Westhuyzen). In this· case, the long retention of
precursors in the ER markedly increases the proportion
of receptor precursors that are degraded and hence the
number of receptors that reach the cell surface.
Class 3 mutants exhibit impaired ligand bir..ding.'








tied, the receptor attains its mature form of apparent
MW 160 kDa. This process normally takes 15-30
minutes. From the Golgi the receptor is transported to
the cell surface where it can bind lipoproteins that bear
its ligands, apolipoprotein B-I00 and/or E. Receptors
are normally concentrated in specific regions of the plas-
ma membrane called coated pits, that mediate endo-
cytosis. Following their uptake, the pH in endocytic
vesicles is lowered by a proton-driven pump. In the
compartment for the uncoupling of the receptor and lig-
and (CURL), the pH is sufficiently low for the receptor
and ligand to dissociate. The ligand is delivered to Iyso-
somes where its apolipoproteins are degraded and the
cholesterol esters are hydrolysed. The liberated free
FIG. 3.
Schematic diagram showing the relationship between





to Golgi ~ (5)
(2)
FIG. 4.
Schematic diagram of the itinerary of the LDL receptor
(IDL =intermediate-density lipoprotein; LDL =low-densi-
ty lipoprotein; ER = endoplasmic reticulum). Numbers in
brackets indicate the class of mutation that results from
interruption of the indicated process.
suggested that integrity of repeats 2 to 7 in the ligand-
binding domain and exon 7 in the EGF-precursor
homology domain was necessary for LDL (apo B) bind-
ing, while only repeat 5 was critical for f3-VLDL (apo E)
binding.30.32 This is exemplified by FH Cape Town-2
(where exons 7 and 8 are deleted),'· which normally
recognises antibodies and apo E-contalning lipoproteins
but does not bind LDL. An interesting variation on this
theme was discovered in the FH Afrikaner-1 mutation
that results in at least 2 different mutant protein sub-
populations being produced from 1 mutant gene that
has a point mutation in exon 4. The one subpopulation
that constitutes about 30% of the receptors normally
recognises apolipoprotein B-100 on LDL, while the
other subpopulation does not bind LDL at all.3l•33 These
2 populations of receptors possibly result from differ-
ently folded forms of the same primary amino acid
sequence. Previously, class 3 mutations were thought of
as homogeneous populations of receptors with impaired
LDL binding.
The cytoplasmic tail of the LDL receptor contains
specific amino acids that are important determinants for
the clustering of receptors in coated pits. Mutations of
these amino acids that result in receptors that bind lig-
and but do not get internalised to any significant extent
are called class 4 mutations.' No South African FH
patient with this rare type of mutation has been identi-
fied.
In 1990, a fifth class of mutation was defined. These
were recycling-defective receptors that failed to separate
from bound ligand after being internalised in endo-
somes. Such receptors are trapped in the cell in the
presence of ligand and are unable to return to the cell
surface. These receptors are rapidly degraded as a
result.' The FH Cape Town-2 mutation,'· a deletion of
two exons in the EGF-precursor-like domain found in
coloureds, demonstrates this phenomenon. However,
certain mutations such as FH Afrikaner-23l and FH
Zambia"·20 have been identified that exhibit increased
degradation even in the absence of ligand. These recep-
tors are therefore not being degraded primarily as a con-
sequence of impaired dissociation from their ligands.
The instability of these receptors is of critical impor-
tance since the resulting low steady-state pool of recep-
tors is the cause ofFH in these patients.
Clinical relevance ofFH research in
South Africa
FH is found in more than 1/100 Afrikaners/ Jews' and
Indians in South Africa (personal communication -
H. C. Seftel, M. S. Asvat). The polymerase chain reac-
tion that rapidly amplifies desired target DNA
sequences has revolutionised the diagnosis of many
genetic diseases and has facilitated the design of easy
and reliable methods of screening for these FH muta-
tions at the DNA level (e.g. ref. 12). There are sugges-
tions that the severity and prognosis of FH among
Afrikaners vary according to the type of mutation:
heterozygotes with the FH Afrikaner-1 mutation that
produces a significant number of normal functional
receptors seem to be less affected than those with the
FH Afrikaner-2 mutation whose receptors are so rapidly
degraded in the marure form that there are practically
no mutant receptors found on the cell surface. These
findings complement an earlier study that showed that
FH homozygotes, whose LDL-receptor alle1es expressed
some functional LDL receptors, had lower LDL-choles-
terol levels, bener therapeutic responses and less severe
coronary atherosclerosis than homozygotes whose alleles
produce no receptors. 1 In addition, there have been
recent reports that the response of individuals to the
lipid-lowering drug, simvastatin, is also partly influenced
by the specific mutation in FH heterozygotes. 34 The ease
of screening for these mutations can thus be applied in a
specific, detailed diagnostic sening and for genetic coun-
selling and prenatal diagnosis, especially where there is a
risk of a homozygote child being born (e.g. in Afrikaners
or in Muslim Indians where consanguinity is common).
Monogenic diseases are normally considered to be
exceptionally rare medical curiosities of interest only to
academics. In South Africa, however, FH has a signifi-
cant impact on the health of Afrikaners, Indians and
Jews. Due to the high frequencies of FH in these popu-
lations the prevalence of FH in South Africans in gen-
eral is about 1/250. Therefore this disease must be con-
sidered when dealing with hypercholesterolaemic
individuals or patients with premarure coronary artery
disease.
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and Paul Loewenstein Trust and Old Mutual (South
Africa) for financial support.
REFERENCES
I. Goldsrein JL, Brown MS. Familial hypercholesterolemia. In: Scriver
CR, Beaudet AL, Sly WS, Valle D, eds. The Merabo/ie Basis of
Inherired Disease. 6ffi ed. New York: McGraw-Hill, 1989; 1215-
1250.
2. Innerarity TL, Mahley RW, Weisgraber KH, er at. Familial defective
apolipoprotein B-IOO: a mutation of apolipoprotein B that causes
hypercholesterolemia.] Lipid Res 1990; 31: 1337-1349.
3. Seftel HC, Baker SG, Sandler MP, er at. A host of hypercholestero-
laemic homozygotes in South Africa. BM] 1980; 281: 633-636.
4. Seftel HC, Baker SG, Jenkins T, Mendelsohn D. Prevalence of
familial hypercholesterolemia in Johannesburg Jews. Am] Med
Gener 1989; 34: 545-547.
5. Myanr ~T\V. Cho/esreTo/ Mewbo/ism, LDL and rhe LDL ReeepcoT.
London: Academic Press, 1990.
6. Rubinszrein DC, Cohen JC, Berger GM, Van der \Vesthuyzen DR,
Coetzee GA, Gevers W. Chylomicron remnant clearance from the
plasma is normal in familial hypercholesterolemic subjects with
defined receptor defects.] Clin Invesrl990; 86: 1306-1312.
7. Brown MS, Herz J, Kowal RJ, Goldstein JL. The low-density
lipoprotein-related protein: double agent or decoy. Currenr Opinion
in Lipid%gy 1991; 2: 65-72.
8. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL
receptor locus in familial hypercholesterolemia: mutational analysis
of a membrane protein. Ann Rev Gener 1990; 24: 133-170.
9. Rauh G, Keller CH, Korman B, er al. Familial defective apolipopro-
tein B-100: clinical characteristics of 54 cases. ArheTosclerosis 1992;
92: 233-241.
10. Hfuniiliiinen T, Palotie A, Aalto-Setiilii K, Kontuia K, Tikkanen MJ.
Absence of familial defective apolipoprotein B-IOO in Finnish
patients with elevated serum cholesterol. Arherosclerosis 1990; 82:
177-183.
11. Hosking JL, Baize R, Roach PP, Thomas D. Hypercholesterolaemia
due to familial apolipoprotein B-IOO in tWO Australian families. Med
] Ausr 1991; 155: 572-573.
12. Graadt van Roggen F, Van der Westhuyzen DR, Marais AD,
Gevers W, Coerzee GA. Low density lipoprotein receptor gene
mutations in Afrikaner familial hypercholesterolemic patients: a
comparison of twO geographical areas. Hum Gener 1991; 88: 204-
208.
13. Leitersdorf E, Van der Westhuyzen DR, Coerzee GA, Hobbs HH.
Two common low density lipoprotein receptor gene mutations
cause familial hypercholesterolemia in Afrikaners. ] Clin Irlvesr 1989;
84: 954-961.
14. Korze MJ, Langenhoven E, Warnich L, er at. The identification of
(WO low-density lipoprotein receptor gene mutations in Soum
African hypercholesterolaemia. S Afr Med] 1989; 76: 399-40 I.
15. Korze MJ, Langerhoven E, Wamich L, Du Plessis L, Retief AE.
The molecular basis of familial hypercholesterolaemia in South
African Afrikaners. Ann Hum Gener 1991; 55: 115-121.
16. Defesche Je. The molecular basis and treatment of familial hyper-
cholesterolemia. Ph.D. thesis, University of Amsterdam, 1993.
17. Meiner V, Landsberger D, Berkman N, er at. A common Lithuanian
mutation causing familial hypercholesterolemia in Ashkenazi Jews.
Am] Hum Gener 1991; 49: 443-447.
18. Bhana S, Bain J. Semng Dc>WTl Roors: Indian Migranrs in Sourh Africa.
Johannesburg: Witwatersrand University Press, 1990; 15-43.
19. Soutar AK, Knight BL, Patel DD. Identification of a point mutation
in growffi factor repeat C of the low density lipoprotein-recepror
gene in a patient with homozygous familial hypercholesterolemia
that affects ligand binding and intracellular movement of receptors.
Proe Nar/ Aead Sci USA 1989; 86: 4166-4170.
20. Rubinsztein DC, Coetzee GA, Marais AD, Leitersdorf E, Seftel
HC, Van der Westhuyzen DR. Identification and properties of the
proline"",-leucine mutant LDL receptor in South Africans of Indian
origin.] Lipid Res 1992; 33: 1647-1655.
21. King-Underwood L, Gudnason V, Humphries S, er at. Identi-
fication of the 664 proline to leucine mutation in the low density
lipoprotein receptor in four unrelated patients with familial hyper-
cholesterolemia in the UK. C/in Genel1991; 40: 17-28.
I
-:l1li'-----------------------------
22. Marais AD, Berger GMB. A diversiry of genetic hyperlipopro-
teinaemias in black patients. E,:perience at the lipid clinics at Groote
Schuur Hospital and the Red Cross War Memorial Children's
Hospital, Cape ToWD. S Afr Med J 1986; 70: 583-587.
23. Vermaak WJH, Ubbink JR, Delport R, Becker PJ, Bissban SR,
Ungerer PJ. Ethnic immunity [0 coronary hean disease?
Acherosclerosis 1991; 789: 155-162.
24. Leitersdorf E, Hobbs RH, Fourie AM, Jacobs M, Van der West-
huyzen DR, CoelZee GA. Deletion in the first cysteine-rich repeat of
the low densiry lipoprotein receptor impairs its tranSPOrt but not
lipoprotein binding in fibroblasts from a subject with fantilial hyper-
cholesterolemia. Proc Nad Acad Sci USA 1988; 85: 7912-7916.
25. Hobbs RH, Brown MS, Goldstein JL. Molecular genetics of the
LDL receptor gene in familial hypercholesterolaemia. Human
Mucanon 1992; 1: 445-466.
26. Van der Westhuyzen DR, Stein ML, Henderson HE, Marais AD,
Fourie AM, Coetzee GA. Deletion of two growth-factor repeats
from the low-densiry lipoprotein receptor accelerates its degradation.
BiochemJ 1991; 278: 667-682.
27. Defesche JC, Lamping RJ, Kastelein JJP. The Apo B,_mutation in
Dutch hypercholesterolemic patients. Abstracts of the 9th Inter-
national Symposium on Atherosclerosis, Rosemont, Ill., 6-11 OCt
1991.
28. Rubinsztein DC, Jialal I, Leitersdorf E, Coetzee GA, Van der
Westhuyzen DR Identification of 2 new LDL-receptor mutations
causing familial hypercholesterolemia in a South African of Indian
origin. Biochim Biophys Acta 1993; 1182: 75-82.
29. Casciola LAF, Grant KI, Gevers W, Coetzee GA, Van der West-
huyzen DR Low densiry lipoprotein receprors in human fibroblasrs
are not degraded in Iysosomes. BiochemJ 1989; 262: 681-683.
30. Esser V, Limbird LE, Brown MS, Goldstein JL, Russell nw.
Mutational analysis of the ligand binding domain of the low density
lipoprotem recepror. J BIOI Chem 1988; 263: 13282-13290.
31. Fourie A.M., CoelZee GA, Gevers W, Van der Westhuyzen DR Two
mutant low-densiry lipoprotein receptors in Afrikaners slowly pro-
cessed to surface forms exhibiting rapid degradation or functional
heterogeneity. Biochem J 1988; 255: 411-415.
32. Russell nw, Brown MS, Goldstein JL. Different combinations of
cysteine-rich repeats mediate binding of low density lipoprotein
receptor to tWO different proteins. J Bioi Chem 1989; 264: 21682-
21688.
33. Fourie AM, Coetzee GA, Gevers W, Van der Westhuyzen DR.
Low-densiry lipoprotein recepror point mutation results in expres-
sion of both active and inactive surface forms of the same mutant
receptor. Biochemistry 1992; 311: 12754-12759.
34. Jeenah MS, September W, Graadt van Roggen F, De Villiers W,
Seftel H, Marais AD. Influence of specific mutations at the LDL-
receptor gene locus on the response to simvastatin therapy in
Afrikaner patients with heterozygous familial hypercholesterolemia.
Acherosclerosis 1993; 98: 51-58.
35. Rubinsztein DC. tvionogenic hypercholesterolemia in South
Mricans: familial hypercholesterolemia in Indians and familial
defective apolipoprotein B-IOO. PhD thesis, Universiry of Cape
Town, 1992.
Histologically diagnosed cancers in South Africa, 1988
F. SITAS
Abstract The National Cancer Registry (NCR) collects
infonnation on cancer diagnoses via a nation-wide
network of public and private pathology labora-
tories. In 1988, 45 570 new laboratory-diagnosed
cancer cases were reported to the NCR. Minimal
age-standardised registration rates for black,
white, coloured and Asian males were 112,2, 229,9,
192,2 and 91,6/100 000, respectively, and those for
females 107,2,201,3 148,1 and 118,0. About 40% of
cancers in females and 31,3% in males occurred in
potentially economically active adults aged 15 - 54
years. The top five cancers in males were: (z) basal
cell skin cancer; (iz) cancer of the prostate gland;
(iiz) cancer of the oesophagus; (iv) lung cancer;
and (v) squamous cell skin cancer. In females they
were: (z) cancer of the cervix; (iz) breast cancer;
(iiz) basal cell skin cancer; (iv) squamous cell skin
cancer; and (v) cancer of the oesophagus. Despite
under-reporting, a nwnber of cancers, especially
those of the oesophagus and cervix in blacks and
skin cancers in whites, rank among the highest in
the world. Moreover, 40,4% of the cancers in adult
males (15 - 64 years) and 15,2% of those in adult
females were associated with tobacco use. It is rec-
ommended that: (z) regional cancer registries be
set up in a number of regions to provide informa-
tion on the true burden of cancer and to monitor
interventions; (ii) a national screening pro-
gramme for cancer of the cervix be established;
(iiz) detailed studies on lifestyle and dietary caus-
es, especially of cancers related to tobacco con-
sumption and cancers of the oesophagus, cervix
and skin, be undertaken; and (iv) the impact of
mv on virus-related cancers be monitored.
S Atr Med J 1994: 84: 344-348.
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I n order to assist in the planning and evaluation ofcancer control programmes, the National CancerRegistry (NCR) was established in 1986 to record
the incidence of histologically diagnosed cancer in South




Methods of data collection and coding of cancers are
described elsewhere. I,' Briefly, the NCR collects infor-
mation on incident cases of cancer from a network of
most (85) private and public histopathology and haema-
tology laboratories throughout South Africa (including
Transkei, Ciskei, Bophuthatswana and Venda (TBVC).
From 1988 onwards, data from cytology laboratories
were also included_
Population
Population denominator data were obtained from extra-
polations of the 1985 census to 1988 by the Central
Statistical Services. Estimates of the total population of
the TBVC homelands for 1988 were obtained from the
Epidemiology Directorate of the Deparnnent of Health
and Population Development (R. Swanenvelder) and
added to the South African population data, in propor-
tion to the age structure of the South African population
data.
Cancer registration rates
Age- and sex-specific frequencies of cancer are shown in
Tables I and n. Age-standardised registration rates
(ASR) were calculated using the direct method of stan-
dardisation and the 'world standard population'.
Cumulative lifetime risks (LR) of developing cancer
were calculated using standard procedures.' Calcula-
tions of crude rates, ASR and LR exclude basal and
